trending Market Intelligence /marketintelligence/en/news-insights/trending/4FN1VkO5nUn6Ux2GwEqScg2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Gilead's HIV-1 medicine Biktarvy gets approval in Japan

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Gilead's HIV-1 medicine Biktarvy gets approval in Japan

Gilead Sciences Inc.'s once-daily HIV-1 regimen Biktarvy has been approved for use by Japan's Ministry of Health, Labour and Welfare.

Foster City, Calif.-based Gilead's Biktarvy tablet combines bictegravir and two additional HIV medicines, emtricitabine and tenofovir alafenamide, or Descovy, also manufactured by Gilead.

The Japanese approval was based on data from four phase 3 studies that included 2,415 patients. Two of these studies, dubbed 1489 and 1490, were carried out in HIV-1 infected adults who had never undergone treatment, while the other two studies, known as 1844 and 1878, included virologically suppressed adults. After 48 weeks of treatment, Biktarvy met the main goal of showing non-inferiority to standard therapy in all four studies.

The once-daily single tablet regimen was approved in the U.S. in February 2018 to treat HIV-1 infection.